



1H FY2025 Presentation Material

- Results for 1H FY2025 & Full-Year Forecast -

December 3, 2025


OSAKA SODA CO., LTD.



Results for 1H FY2025

Earnings Trends

- Net sales decreased but income increased YoY for the 1H FY2026
- Profit at each stage reached a second highest level following 1H FY2022
- Net income for 1H 2025 includes an extraordinary gain from investment securities sale



Overview of Consolidated Financial Results

- Net sales declined due to factors including softening market conditions for one product in the functional chemicals business
- Operating income exceeded YoY and initial forecasts due to the resolution of production problems in basic chemicals, cost reduction initiatives, and improved market conditions

(Million of yen)	1H FY2024		1H FY2025		Change (YoY)	Change (YoY)	Initial forecast (B)	Achievement rate	Change (A)-(B)
		to sales	(A)	to sales					
Net sales	50,167	—	48,832	—	(1,335)	(2.7)%	50,200	97.3%	(1,368)
Operating income	6,967	13.9%	8,111	16.6%	1,144	16.4%	8,000	101.4%	111
Ordinary income	7,185	14.3%	8,910	18.2%	1,725	24.0%	8,500	104.8%	410
Net income	4,866	9.7%	6,755	13.8%	1,889	38.8%	5,700	118.5%	1,055
Earning per share	¥ 38.36	—	¥ 53.74	—	—	—	—	—	—
Overseas sales	19,512	38.9%	18,833	38.6%	(679)	(3.5)%	—	—	—


Assumptions		1H FY2024	1H FY2025
Average exchange rate	Yen / USD	154 Yen	147 Yen
	Yen / Euro	167 Yen	167 Yen
Naphtha price	Yen / KL	79,000 Yen	64,500 Yen

Segment (Basic Chemicals)

- **Basic chemicals** : Cost reduction initiatives made a significant contribution
- **Chlor-Alkali** : Resolved production problems contributed to improved unit costs and increased production volume
- **Epichlorohydrin** : Improved market conditions and higher sales volume contributed

(Millions of yen)

■ Net sales ■ Operating income




Net sales (up ¥1.9 billion YoY)

Chlor-Alkali	+0.1
Epichlorohydrin	+1.8

Variance (Operating income, YoY)

(Billions of yen)




Segment (Functional Chemicals)

- **Synthetic rubber** : Acrylic rubber sales remain steady, mainly for China and Asia, while epichlorohydrin rubber sales for automotive applications in Europe are sluggish
- **Synthetic resin** : DAP monomer for building materials increased demand for replacement from competing products and Non-phthalate allyl resin increased new applications for UV inks
- **Allyl ethers** : Strong decline in Chinese market conditions, and decline in European demand for Silane coupling agents

(Millions of yen)


■ Net sales ■ Operating income



Net sales (down ¥2.3 billion YoY)	
Synthetic rubber / Synthetic resin	(0.2)
Allyl ethers	(1.0)
etc.	(1.1)


Variance (Operating income, YoY)

(Billions of yen)




Segment (Healthcare)

- **Chromatography** : Silica gel business grew on strong demand for diabetes and obesity medications, offsetting higher depreciation at Matsuyama through increased volume
- **APIs and their intermediates** : Affected by the decreased sales of intermediates for diabetes medication and others
- Amagasaki 2nd Phase Expansion for silica gel was completed in September 2025, 1 year ahead of initial schedule



Net sales (up ¥0.5 billion YoY)	
Chromatography*	+0.8
APIs and their Intermediates	(0.3)




* Pharmaceutical purification materials(Silica gel), analytical equipment, packed columns

Segment (Trading and Others)

- **Consumer products** : Sales remained steady
- **Specialty Polymer Materials** : Sales of printing-related products remained sluggish
- **Others** : Sales of inorganic chemicals declined

(Millions of yen)

■ Net sales ■ Operating income




Net sales (down ¥1.4 billion YoY)

Consumer products	+0.4
Specialty Polymer Materials	(0.3)
Building Materials	(0.1)
Basic chemicals products, etc.	(1.4)

Variance (Operating income, YoY)

(Billions of yen)



Balance Sheet, Statement of Cash Flows

- Our stable financial foundation was recognized, and the credit rating by Rating and Investment Information, Inc. (R&I) was upgraded by one notch from A- to A
- The acquisition of treasury stock (¥1 billion) in August this year increased cash used in financing activities compared YoY

(Million of yen)	1H FY2024	FY2024	1H FY2025	Change from FY2024
Total assets	153,061	153,935	159,437	5,502
Net assets	112,739	115,596	121,618	6,022
Shareholder's equity ratio	73.7%	75.1%	76.3%	1.2%
Interest-bearing debt	7,656	7,635	7,172	(463)

(Million of yen)	1H FY2024	FY2024	1H FY2025	Change from 1H FY2024
Cash flows from operating activities	10,117	17,049	7,988	(2,129)
Cash flow from investing activities	(4,483)	(8,135)	(2,733)	1,750
Cash flow from financing activities	(1,226)	(4,221)	(2,724)	(1,498)
Cash and cash equivalents	42,963	43,314	45,587	2,624



Forecast for FY2025

Forecast for FY2025

- Expect continued profit growth driven by improved market conditions in the basic chemicals business and expansion in the healthcare business
- Further upward revision of the initial full year forecast, which projected record profits

(Million of yen)	FY2024		FY2025 Forecast		Change (YoY)	
		To sales (%)		To sales (%)	Amount	Percentage (%)
Net sales	96,434	—	102,000	—	5,566	105.8
Operating income	13,246	13.7	17,300	17.0	4,054	130.6
Ordinary income	14,154	14.7	18,700	18.3	4,546	132.1
Net income	10,332	10.7	13,500	13.2	3,168	130.7
Earning per share	81.54 Yen	—	108.28 Yen	—	—	—
Overseas sales	36,184	37.5	39,300	38.5	3,116	108.6

Assumptions		FY2024	FY2025 Forecast
Average exchange rate	Yen / USD	152 Yen	145 Yen
	Yen / Euro	163 Yen	160 Yen
Naphtha price	Yen / KL	75,800 Yen	64,000 Yen

FY2025 Forecast by Segment


- **Basic chemicals** : Strong profit growth expected from better epichlorohydrin market and cost reductions
- **Functional chemicals** : While the allyl ether market recovers more slowly than anticipated, expanded sales of synthetic rubber and other products expected to keep results at previous year
- **Healthcare** : Effect of increased silica gel production expected from early 2026

		FY2024			FY2025 Forecast			Change (YoY)		
(Millions of yen)		1H	2H	Full Year	1H	2H	Full Year	1H	2H	Full Year
Net sales	Basic Chemicals	18,403	19,233	37,636	20,302	21,798	42,100	1,899	2,565	4,464
	Functional Chemicals	15,963	13,134	29,097	13,596	15,604	29,200	(2,367)	2,470	103
	Healthcare	6,172	7,512	13,684	6,709	8,291	15,000	537	779	1,316
	Trading and Others	9,627	6,388	16,015	8,223	7,477	15,700	(1,404)	1,089	(315)
	Total	50,167	46,267	96,434	48,832	53,168	102,000	(1,335)	6,901	5,566
Operating income	Basic Chemicals	1,047	1,228	2,275	2,946	2,954	5,900	1,899	1,726	3,625
	Functional Chemicals	2,560	1,767	4,327	1,926	2,424	4,350	(634)	657	23
	Healthcare	3,424	3,607	7,031	3,447	4,353	7,800	23	746	769
	Trading and Others	570	334	904	462	288	750	(108)	(46)	(154)
	Company-wide, eliminations	(635)	(658)	(1,293)	(671)	(829)	(1,500)	(36)	(171)	(207)
	Total	6,967	6,278	13,246	8,111	9,189	17,300	1,144	2,911	4,054


Segment (Basic Chemicals)

Toward achieving full production and full sales with existing capacity :

- **Chlor-Alkali** : Continue safe and stable operations and strengthen regionally-based sales
- **Epichlorohydrin** : Strengthen overseas sales to drive market share expansion




Net sales (up ¥4.4 billion YoY)	
Chlor-alkali	+1.6
Epichlorohydrin	+2.8




Segment (Functional Chemicals)

- **Synthetic rubber** : Expect gradual recovery in automobile production volume; utilize acrylic rubber facility capacity to secure new adoptions both domestically and internationally
- **Synthetic resin** : Strive to grow market share for UV offset inks through sales expansion in Europe, U.S., and Asian markets
- **Allyl ethers** : Maintain and expand market share through flexible sales strategies responding to market fluctuations



Net sales (up ¥0.1 billion YoY)	
Synthetic rubber / Synthetic resin	+0.8
Allyl ethers	(0.1)
etc.	(0.6)




Topics: Enhancement of Allyl Ethers


- Allyl glycidyl ether is used as a raw material for epoxy-based silane coupling agents
- Demand is projected to grow steadily at an annual rate of 3–4%
- In October 2025, a decision was made to expand allyl ether production capacity (scheduled for completion in March 2027, approx. 1.2 times the current capacity)
- In December 2025, the expansion of the allyl ether shipping facility was completed (approx. double the current capacity)

Trends in Sales Volume and Manufacturing Capacity

(times)



Global Shares (Allyl Ethers)




Segment (Healthcare)

- **Chromatography** : Demand for diabetes and obesity treatments continues to expand, and promotion of sales for biosimilars
- Incorporate the revenue contribution from the Matsuyama Plant and the second-phase expansion of the Amagasaki Plant after the beginning of the new year
- **APIs and their intermediates** : Installed a GMP-compliant dedicated vessel for biopharmaceuticals in July 2025, focusing on securing new contract manufacturing projects

(Millions of yen)

Net sales — Operating income




Net sales (up ¥1.3 billion YoY)	
Chromatography*	+1.3
APIs and their Intermediates	±0.0

* Pharmaceutical purification materials(Silica gel), analytical equipment, packed columns

Variance (Operating income, YoY)

(Billions of yen)




Segment (Trading and Others)

- **Consumer products** : Factor in increased sales of planned products and semi-solid-state batteries
- **Functional products** : Expect steady demand for glass fiber and other products, especially in the electronics materials sector
- **Basic chemicals products** : Sales of inorganic chemicals are expected to remain sluggish

(Millions of yen)


■ Net sales ■ Operating income



Net sales (down ¥0.3 billion YoY)	
Consumer products	+0.7
Functional products	+0.3
Specialty Polymer Materials	(0.3)
Basic chemicals products, etc.	(1.0)


Variance (Operating income, YoY)

(Billions of yen)



Shareholder Returns

- Following the upward revision of full-year earnings, the FY2025 dividend was raised by ¥5 to ¥25
- To enhance shareholder returns, the company decided on Nov 7 to repurchase ¥5 billion in shares, bringing the total (including ¥1 billion in August) to ¥6 billion, with the payout ratio expected to exceed 40%



Share buyback (Billion Yen)	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025(Plan)
	1.6	—	1.0	—	2.2	0.8	1.8	6.0*

* Figures include the planned amount for the acquisition of treasury stock, decided on November 7, 2025, with an acquisition period from November 10, 2025, to January 30, 2026, and an acquisition price capped at 5 billion yen.




※ Figures for dividend per share is converted after the stock split.(effective October 1, 2024)



Silica Gel Business Expansion

Toward capturing emerging market demand


- Since 2022, peptide pharmaceutical companies in emerging markets have grown 4.5 times in 5 years
- The expansion of the medium-molecule drug market and the rise of the obesity medication market are driving new corporate entries
- Strengthened sales efforts in India and China, achieving adoption by about 70% of target companies
- Complete coverage of potential customers to capture robust demand for obesity medications



Silica Gel Expansion Plans and Demand Trends


- Demand expansion prompted the early commencement of operations for the Matsuyama and Amagasaki 2nd Phase expansion
- Patent expirations for obesity medications accelerate entry of generic China and India
- Assumes demand will exceed current production capacity by 2028; plans to determine next expansion within this year

Our Production Capacity and Silica Gel Demand Forecast



Development of ADME Gels


- Developed ADME gel with an original modifying group as a new pharma-grade purification solution
- Combines hydrophobic and hydrophilic properties, delivering unique separation performance beyond conventional modifiers
- Expected to be applied to nucleic acid drugs, a market anticipated to grow further
- Started sample work globally for adoption purposes




Features of ADME Gel

- Structure with close proximity to a hydrophilic silica surface despite its hydrophobicity
- Ability to separate substances that could not be separated using conventional modifying groups, due to affinity with hydrophilic nucleic acid bases

Separate Performance Comparison with C18 Grade





Contact : Osaka Soda Co., LTD.
Public Relations Group, Corporate Planning Department
TEL : 06-7733-1005

This document is not prepared for the purpose of soliciting investment in securities issued by us.
All information contained in this document represents our views as of the time of preparation of this document.
Please note that we do not guarantee or promise accuracy and completeness.